AI-generated summary
The authors studied intranasal irradiation with a 308 nm xenon chloride ultraviolet B laser in patients with severe allergic rhinitis in an open study. In the medium-dose group, treatment significantly reduced rhinorrhoea, sneezing, nasal obstruction and total nasal score, while the low-dose group showed no improvement. The authors suggest the laser might be a new therapeutic tool, though the study was small and open-label.
- Who or what was studied
- Patients with severe allergic rhinitis, divided into a low-dose group (n=10, seven completed) and a medium-dose group (n=8)
- Wavelengths
- 308 nm
- Limits stated in the abstract
- Small open-label study with no control group, and the authors describe the findings as suggestive rather than conclusive.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 308 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Dose, Ultraviolet. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.